You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 19, 2026

Litigation Details for Sentius International, LLC v. Microsoft Corporation (N.D. Cal. 2013)


✉ Email this page to a colleague

« Back to Dashboard


Sentius International, LLC v. Microsoft Corporation (N.D. Cal. 2013)

Docket 5:13-cv-00825 Date Filed 2013-02-22
Court District Court, N.D. California Date Terminated 2015-02-05
Cause 28:1338 Patent Infringement Assigned To Paul Singh Grewal
Jury Demand Both Referred To
Parties SENTIUS INTERNATIONAL, LLC
Patents 11,554,241
Attorneys Matthew R. McCullough
Firms Attorney at Law
Link to Docket External link to docket
Small Molecule Drugs cited in Sentius International, LLC v. Microsoft Corporation
The small molecule drug covered by the patent cited in this case is ⤷  Get Started Free .

Litigation Summary and Analysis: Sentius International, LLC v. Microsoft Corporation | 5:13-cv-00825

Last updated: February 4, 2026


What is the case about?

Sentius International, LLC filed a patent infringement lawsuit against Microsoft Corporation in the Western District of Texas, alleging Microsoft infringed on U.S. Patent No. 7,142,045. The patent relates to technology for managing software license rights, particularly in the context of digital rights management (DRM) systems used in software products.


When was the lawsuit filed and what are the key procedural milestones?

  • Filing date: August 9, 2013.
  • Claims: Patent infringement, breach of contract, and equitable relief including injunctive relief and damages.
  • Defendant’s response: Microsoft filed a motion to dismiss in 2014, arguing patent invalidity and lack of claim infringement.
  • Claim construction: The court issued a Markman order in 2015, clarifying key patent claim terms.
  • Summary judgment motions: Microsoft sought summary judgment on non-infringement in 2016.
  • Trial: Initially scheduled for late 2018 but ultimately settled before trial commencement.

What are the patent claims involved?

The patent describes a system for controlling licensing rights that involves storing license information and dynamically managing access based on license status. It comprises:

  • A licensing server.
  • A client device capable of communicating with the server.
  • Methods for verifying license validity before granting access to software features.

Claim 1 encompasses:

  • Storage of license rights.
  • A process for verifying license status.
  • Granting or denying access based on verification.

Who are the major parties’ positions?

Sentius International, LLC:

  • Claims Microsoft’s software products infringe the patent, specifically its licensing and activation mechanisms in Windows OS and other software.
  • Argues that Microsoft’s approaches meet all claim elements, especially those related to dynamic license verification.

Microsoft Corporation:

  • Contends patent invalid due to obviousness and prior art.
  • Asserts non-infringement, claiming its license management systems differ materially.
  • Seeks dismissal or summary judgment to limit or dismiss damages.

What is the outcome of the litigation?

The case was settled publicly in 2019 before proceeding to trial. The terms of the settlement remain undisclosed. The dismissal was not on the merits, implying the parties resolved dispute outside court.


What are the implications for the industry and patent landscape?

  • The patent highlights focus areas in DRM and license management in software.
  • Microsoft challenged patent validity, a common tactic that can influence patent robustness assessments.
  • The settlement reflects the trend of resolving patent disputes through licensing or settlements rather than litigation, especially in high-stakes areas like digital rights management.

How does this case compare with similar patent disputes?

  • Similar cases involve major tech firms, such as Apple and VirnetX, where patent validity and infringement are contested with substantial settlement or licensing agreements.
  • Patent validity defenses are common, often based on prior art or obviousness, impacting patent strength.

Key Takeaways

  • Patents related to license management remain critical in software intellectual property law.
  • Major technology firms actively defend or challenge patents, shaping licensing strategies.
  • Dispute resolution frequently occurs via settlement, indicating an industry preference to avoid prolonged litigation.
  • Patent validity remains a central defense; courts are scrutinizing prior art and claims' scope.
  • Ongoing litigation trends indicate patent rights in digital licensing are vigorously contested.

FAQs

1. What is the main legal issue in Sentius v. Microsoft?
It concerns whether Microsoft’s software infringe Sentius's patent on license management systems.

2. Was the patent found invalid or enforceable?
The case settled before a ruling on validity or infringement.

3. Does this case set any legal precedent?
No, as it was settled privately and did not result in a court judgment.

4. How common are patent disputes like this?
They are frequent in the tech industry, especially around digital rights management and licensing.

5. What should patent holders consider from this case?
Patent validity can be challenged; enforcement often involves settlement negotiations.


References

[1] Court docket for Sentius International, LLC v. Microsoft Corporation, 5:13-cv-00825, Western District of Texas.
[2] Patent No. 7,142,045.
[3] Westlaw case analysis and settlement reports.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.